8-K: Entero Therapeutics Appoints Forvis Mazars as New Independent Auditor Following Mazars Merger

Entero Therapeutics has appointed Forvis Mazars as its new independent auditor, effective June 1, 2024, following a merger involving its previous auditor, Mazars USA LLP.

Summary

• Entero Therapeutics has changed its independent registered public accounting firm from Mazars USA LLP to Forvis Mazars, LLP, effective June 1, 2024.
• This change occurred because Mazars USA LLP merged with FORVIS, LLP, which then changed its name to Forvis Mazars, LLP.
• The Audit Committee of Entero's Board of Directors approved the appointment of Forvis Mazars, subject to stockholder ratification at the next annual meeting.
• Mazars' audit reports for the fiscal years ended December 31, 2023 and 2022 did not contain any adverse opinions, disclaimers, or qualifications.
• There were no disagreements between Entero and Mazars on any accounting principles, financial statement disclosures, or auditing procedures during the fiscal years ended December 31, 2023 and 2022, and the subsequent interim period.
• Mazars confirmed that they did not advise Entero of any matters specified in Item 304(a)(1)(v) of Regulation S-K.
• Entero did not consult with Mazars on any accounting principles or audit opinions that were a factor in reaching a decision on any accounting, auditing or financial reporting issue.
• Entero also did not consult with Forvis Mazars regarding any of the matters set forth in Items 304(a)(2)(i) and (ii) of Regulation S-K.

Sentiment

Score: 8

Explanation: The document indicates a smooth transition of auditors with no reported issues, suggesting a positive and well-managed change. The lack of disagreements and clean audit reports from the previous auditor further support a positive sentiment.

Positives

• The transition to a new auditor appears to be smooth, with no reported disagreements or issues with the previous auditor, Mazars.
• Mazars' audit reports for the past two fiscal years were clean, indicating a healthy financial reporting environment.
• The new auditor, Forvis Mazars, was appointed by the Audit Committee, suggesting a thorough selection process.

Risks

• The change in auditor could introduce some short-term uncertainty, although the transition appears to be well-managed.
• The appointment of Forvis Mazars is subject to stockholder ratification, which could pose a minor risk if not approved.

Future Outlook

The company will seek stockholder ratification of the appointment of Forvis Mazars at the next annual meeting.

Industry Context

Changes in auditing firms are not uncommon, especially following mergers or acquisitions within the accounting industry. This change appears to be a direct result of the Mazars-FORVIS merger, which is a significant event in the accounting sector.

Comparison to Industry Standards

• The transition of auditors due to mergers is a common occurrence in the accounting industry, with firms like Deloitte, Ernst & Young, KPMG, and PwC also experiencing similar changes through their history.
• The lack of disagreements between Entero and Mazars is a positive sign, as it indicates a healthy relationship and adherence to accounting standards, which is consistent with best practices in the industry.
• The appointment of Forvis Mazars by the Audit Committee is also a standard practice, ensuring that the selection process is thorough and independent.

Stakeholder Impact

• Shareholders will need to ratify the appointment of Forvis Mazars at the next annual meeting.
• The change in auditor is not expected to have a significant impact on employees or other stakeholders.

Next Steps

• The appointment of Forvis Mazars will be subject to ratification by the company's stockholders at the next annual meeting.

Key Dates

Keywords

auditor, accounting, Mazars, Forvis Mazars, financial statements, audit, Entero Therapeutics, merger